Literature DB >> 9328142

Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy.

K T Kelsey1, D Ross, R D Traver, D C Christiani, Z F Zuo, M R Spitz, M Wang, X Xu, B K Lee, B S Schwartz, J K Wiencke.   

Abstract

The NAD(P)H quinone oxidoreductase (NQO1:EC 1.6.99.2) is an important biotransformation enzyme system that is also known to metabolize important novel chemotherapeutic compounds. The gene that codes for this enzyme has recently been found to be polymorphic in humans. Here, we describe the ethnic distribution of the polymorphism and note that this may have implications for anti-tumour drug development and use.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9328142      PMCID： PMC2228056          DOI： 10.1038/bjc.1997.474

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  14 in total

Review 1.  DT-diaphorase and cancer chemotherapy.

Authors:  R J Riley; P Workman
Journal:  Biochem Pharmacol       Date:  1992-04-15       Impact factor: 5.858

2.  Secondary leukaemia after MMM combined modality therapy for breast carcinoma.

Authors:  N J Philpott; D H Bevan; E C Gordon-Smith
Journal:  Lancet       Date:  1993-05-15       Impact factor: 79.321

3.  The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9.

Authors:  M I Walton; P J Smith; P Workman
Journal:  Cancer Commun       Date:  1991-07

4.  Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells.

Authors:  D Siegel; N W Gibson; P C Preusch; D Ross
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

Review 5.  Response to treatment of breast cancer.

Authors:  J L Berenberg
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

6.  NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity.

Authors:  R D Traver; T Horikoshi; K D Danenberg; T H Stadlbauer; P V Danenberg; D Ross; N W Gibson
Journal:  Cancer Res       Date:  1992-02-15       Impact factor: 12.701

7.  Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.

Authors:  R M Elledge; G M Clark; G C Chamness; C K Osborne
Journal:  J Natl Cancer Inst       Date:  1994-05-04       Impact factor: 13.506

Review 8.  Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase.

Authors:  P Workman
Journal:  Oncol Res       Date:  1994       Impact factor: 5.574

Review 9.  Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies.

Authors:  D Ross; H Beall; R D Traver; D Siegel; R M Phillips; N W Gibson
Journal:  Oncol Res       Date:  1994       Impact factor: 5.574

10.  A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity.

Authors:  D Ross; R D Traver; D Siegel; B L Kuehl; V Misra; A M Rauth
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640
View more
  45 in total

Review 1.  Benzene, NQO1, and genetic susceptibility to cancer.

Authors:  M T Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

2.  Role of NQO1 609C>T and NQO2 -3423G>A gene polymorphisms in esophageal cancer risk in Kashmir valley and meta analysis.

Authors:  Manzoor Ahmad Malik; Showkat Ali Zargar; Balraj Mittal
Journal:  Mol Biol Rep       Date:  2012-06-27       Impact factor: 2.316

3.  High throughput genotyping for the detection of a single nucleotide polymorphism in NAD(P)H quinone oxidoreductase (DT diaphorase) using TaqMan probes.

Authors:  M M Shi; S P Myrand; M R Bleavins; F A de la Iglesia
Journal:  Mol Pathol       Date:  1999-10

4.  Prognostic significance of NQO1 expression in intrahepatic cholangiocarcinoma.

Authors:  Toshifumi Wakai; Yoshio Shirai; Jun Sakata; Yasunobu Matsuda; Pavel V Korita; Masaaki Takamura; Yoichi Ajioka; Katsuyoshi Hatakeyama
Journal:  Int J Clin Exp Pathol       Date:  2011-04-10

5.  Association of NQO1 rs1800566 polymorphism and the risk of colorectal cancer: a meta-analysis.

Authors:  Rui Ding; Shilei Lin; Daojun Chen
Journal:  Int J Colorectal Dis       Date:  2012-01-04       Impact factor: 2.571

6.  Genetic polymorphisms of NQO1, CYP1A1 and TPMT and susceptibility to acute lymphoblastic leukemia in a Tunisian population.

Authors:  Slah Ouerhani; Nouha Cherif; Ikbel Bahri; Ines Safra; Samia Menif; Salem Abbes
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

7.  Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to radiation-induced myeloproliferative disease.

Authors:  Karim Iskander; Roberto J Barrios; Anil K Jaiswal
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

8.  Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves.

Authors:  Jee-Eun Chung; Byung Chul Chang; Kyung Eun Lee; Joo Hee Kim; Hye Sun Gwak
Journal:  Eur J Clin Pharmacol       Date:  2015-08-11       Impact factor: 2.953

9.  Relationships between metabolic and non-metabolic susceptibility factors in benzene toxicity.

Authors:  David Ross; Hongfei Zhou
Journal:  Chem Biol Interact       Date:  2009-11-24       Impact factor: 5.192

10.  NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells.

Authors:  Seema Singh; Muhammad Zahid; Muhammad Saeed; Nilesh W Gaikwad; Jane L Meza; Ercole L Cavalieri; Eleanor G Rogan; Dhrubajyoti Chakravarti
Journal:  J Steroid Biochem Mol Biol       Date:  2009-07-21       Impact factor: 4.292
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.